Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $43.57 USD
Change Today -1.72 / -3.80%
Volume 9.0M
As of 8:04 PM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by ABBOTT LABORATORIES (ABT) in the last 6 months

Announced 08/13/15
Vacant Office Building in Las Colinas
Merger/Acquisition

Bryan J. Kaminski, W.A. Peavy and Mariner Real Estate Management acquired Vacant Office Building in Las Colinas from Abbott Laboratories (NYSE:ABT) on August 13, 2015. Fults Commercial Real Estate has been hired to market the property. Tom Strohbehn and Scot C Farber with Cushman & Wakefield of Texas Inc brokered the sale. Mark West and Adam Herrin with Holliday Fenoglio Fowler provided investment advisory services.


ABT's price was unchanged after the transaction was announced on 08/13/15.
Investor / Buyer
Mariner Real Estate Management LLC
Creditor / Lender
Abbott Laboratories
 
Announced 07/30/15
250.00M for Tendyne Holdings Inc.
Merger/Acquisition

Abbott Laboratories (NYSE:ABT) entered into an agreement to acquire the remaining 90% stake in Tendyne Holdings Inc. from Apple Tree Partners and others for $250 million in cash on July 30, 2015. The deal includes an upfront payment of $225 million and potential future payments of $25 million tied to regulatory milestones. In a separate transaction, Abbott has provided capital and secured an option to purchase Cephea Valve Technologies. Abbott already made a $25 million ...
Read More


ABT's price was unchanged after the transaction was announced on 07/30/15.
Investor / Buyer
Abbott Laboratories
Creditor / Lender
Apple Tree Partners
 
Announced 04/9/15
CynoGen Inc.
Merger/Acquisition

Prelude Corporation agreed to acquire CynoGen Inc. from Abbott Laboratories (NYSE:ABT) on April 9, 2015. Jones Day acted as legal advisor for Abbott Laboratories.


ABT's price was unchanged after the transaction was announced on 04/9/15.
Investor / Buyer
Prelude Corporation
Creditor / Lender
Abbott Laboratories
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABT:US $43.57 USD -1.72

ABT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,072 GBp +38.50
Biogen Inc $292.50 USD -4.80
Danaher Corp $84.79 USD -2.23
Eli Lilly & Co $79.80 USD -2.55
Thermo Fisher Scientific Inc $121.45 USD -3.92
View Industry Companies
 

Industry Analysis

ABT

Industry Average

Valuation ABT Industry Range
Price/Earnings 29.0x
Price/Sales 3.3x
Price/Book 2.9x
Price/Cash Flow 13.2x
TEV/Sales 2.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBOTT LABORATORIES, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.